|
|
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
Casirivimab and imdevimab for patients hospitalised due to COVID-19
|
| Broadcast content: |
|
The combination monoclonal antibody casirivimab plus imdevimab (marketed as Ronapreve®) should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised to manage the symptoms of COVID infection and who are either aged 50 and over, OR aged 12 to 49 AND considered immunocompromised.
Updated versions of both attachments published on 17/09/21 - 20:00 Change to p4 of the alert to remove the word 'Chugai' Change to p5 of the policy to reflect that any suspected adverse reactions should be reported.
|
| Additional information: |
|
NHS Trusts and Foundation Trusts are asked to ensure this alert is shared with Pathology Directors / networks.
This alert is not relevant to primary care.
|